tbuckley/cabot-search huggingface dataset:
Abstract 18449: Apolipoprotein B/Apolipoprotein A-I Ratio and Progression of Aortic Valve Stenosis - Results From the PROGRESSA Study
Authors: Lionel Tastet, Romain Capoulade, Mylene Shen, Abdellaziz Dahou, Marie-Annick A Clavel, Patrick Mathieu, Marie Arsenault, Élisabeth Bédard, Jean-Gaston G Dumesnil, Jean-Pierre P Després, Philippe Pibarot
Journal: Circulation (2015)

Introduction: Calcific aortic stenosis (AS) is an active and complex disorder, which involves atherosclerotic-like processes. However, previous studies reported that the association between atherosclerotic risk factors and AS progression appears to be stronger in younger middle-aged patients compared to elderly ones. Hypothesis: Apolipoprotein B/apolipoprotein A-I (apoB/apoA-I) ratio reflects the balance between proatherogenic versus antiatherogenic lipid profile. The objective of this study was to examine the association between apoB/apoA-I ratio and progression of AS according to patient’s age. Methods: One hundred sixty five patients with AS were prospectively recruited in the PROGRESSA study. AS progression was assessed by increase in peak aortic jet velocity (Vpeak) measured by Doppler echocardiography between baseline and 2-year follow-up. Blood samples were collected to measure plasma levels of apoB and apoA-I. Results: The mean age was 66±13 years and 72% were male. During the 2-year follow-up, AS progression was similar in younger patients (age &lt;69 y.o. [median age for the whole cohort]; n=82) and older patients (Vpeak: +0.24±0.04 vs +0.25±0.03 m/s; p=0.82). There was a significant interaction (p&lt;0.01) between patient’s age and baseline apoB/apoA-I ratio for AS progression. Younger patients with high baseline apoB/apoA-I ratio (i.e. apoB/apoA-I ≥0.53; n=41) had faster AS progression compared to those with lower apoB/apoA-I ratio (Vpeak: +0.32±0.06 vs +0.16±0.04 m/s; p=0.03). In older patients, there was no significant association between apoB/apoA-I ratio and AS progression (Vpeak: +0.23±0.05 vs +0.27±0.04 m/s; p=0.55). After adjustment for sex, hypertension, dyslipidemia, diabetes, metabolic syndrome, creatinine level, degree of aortic valve calcification and baseline Vpeak, higher apoB/apoA-I ratio remained independently associated with faster progression of AS in younger patients (p=0.003). Conclusions: This prospective study shows for the first time that higher apoB/apoA-I ratio is a powerful and independent predictor of faster AS progression in younger patients. These findings suggest that the pathological processes involved in the progression of AS are different in younger versus older patients.
FRI0183 Pregnancy Outcomes in Women Exposed To Infliximab (Innovator): Table 1.
Authors: J. Slater, J. Phillips, C.-Y. Guo, M. Clark, A. Geldhof, N. Gearhart, R. Nissinen
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rheumatologic, dermatologic and inflammatory bowel disorders (IBD) can affect women of childbearing potential. Infliximab ([IFX], Innovator) is approved for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), Crohn9s disease (CD), ulcerative colitis (UC) and psoriasis (PsO). <h3>Objectives</h3> To characterize pregnancy outcomes in patients treated with IFX (Innovator), data obtained from maternal exposure to IFX (Innovator) are presented. <h3>Methods</h3> Dataset includes individual patient cases within the company safety database through 23 August 2015. Cases originated from various sources, including spontaneous reporting, clinical studies, and registries. Cases include prospectively reported (ie, pregnancy outcome not known when first reported) maternal exposures to IFX (Innovator) during pregnancy or within 2 months prior to conception with a known pregnancy outcome in RA, PsA, AS, CD, UC, or PsO pts. Birth outcome was stratified by grouped indication. <h3>Results</h3> <h3>Conclusions</h3> Pregnancy outcomes among pregnancies with T1 IFX (Innovator)-exposure did not differ from the pregnancy outcomes among all prospectively reported pregnancies exposed to IFX (Innovator). Higher percentages of CA were reported among rheumatological indications in comparison to IBD and PsO. The combined rate of CA among pregnancies with IFX (Innovator) exposure was comparable to US general population (3%)<sup>1</sup>. Potential confounders will be further characterized. Limitations of this analysis include lack of a direct comparison group and missing data in the reports. <h3>References</h3> Birth Defects. Centers for Disease Control and Prevention. http://www.cdc.gov/ncbddd/birthdefects/data.html. Accessed 14JAN16 <h3>Disclosure of Interest</h3> J. Slater Employee of: Janssen Scientific Affairs, LLC, J. Phillips Employee of: Janssen Scientific Affairs, LLC, C.-Y. Guo Employee of: Janssen Scientific Affairs, LLC, M. Clark Employee of: Janssen Scientific Affairs, LLC, A. Geldhof Employee of: Janssen Biologics Europe, N. Gearhart Employee of: Janssen Scientific Affairs, LLC, R. Nissinen Employee of: Janssen Biologics Europe
Phase 1 Dose-Escalation Study of PF-04449913, An Oral Hedgehog (Hh) Inhibitor, in Patients with Select Hematologic Malignancies
Authors: Catriona Jamieson, Jorge E. Cortes, Vivian Oehler, Michele Baccarani, Hagop M. Kantarjian, Cristina Papayannidis, Kristen N. Rice, Xiaoxi Zhang, Naveed Shaik, Rachel Courtney, Wendy J. Levin, Giovanni Martinelli
Journal: Blood (2011)
Treatment of Donor Graft Failure with Autologous or Allogenenic Stem-Cell Boost or a Second Allogeneic Transplant Based on Chimerism Testing.
Authors: Avichai Shimoni, Noga Shem-Tov, Avital Rand, Elena Ribakovsky, Ronit Yerushalmi, Izhar Hardan, Arnon Nagler
Journal: Blood (2007)
Cutis laxa acquisita: novel insights into impaired elastic fibre regeneration
Authors: P. Gkogkolou, K. Hildebrandt, S. Broekaert, D. Metze, G. Sengle, M. Böhm
Journal: British Journal of Dermatology (2016)

Cutis laxa (CL) is a rare disorder affecting elastic fiber formation1. The disease is disfiguring and involvement of big vessels in lung and heart often leads to severe complications. CL occurs as an inherited and acquired form, cutis laxa acquisita (CLA). While in the inherited form most mutations have been identified in genes for elastic fiber components like elastin 2, fibulin-4 3, fibulin-5 4, or LTBP-4 5 the pathogenesis of CLA remains poorly understood. Clinically, there often is an association between CLA and paraproteinemia 1. Deposition of immunoglobulins and complement has been proposed to result in an immune-mediated destruction of elastic fibers 6.

This article is protected by copyright. All rights reserved.
Treosulfan-Based Reduced Toxicity Regimen Prior to Allogeneic Hematopoietic Cell Transplantation in Non-Malignant Disorders.
Authors: Jerzy Wojnar, Sebastian Giebel, Miroslaw Markiewicz, Malgorzata Krawczyk-Kulis, Iwona Wylezol, Beata Stella-Holowiecka, Tomasz Kruzel, Jerzy Holowiecki
Journal: Blood (2006)
AB0073 A Value of Pulse Therapy in The Treatment of Relapsing Polychondritis
Authors: M.M. Tashpulatova, E.R. Djuraeva, N.A. Ganiyeva, K.E. Azadayeva
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Relapsing polychondritis (RP) - is a rare systemic disease with undulating course, presumably autoimmune origin characterized by recurring exacerbations of inflammation in the cartilage tissue, leading to their destruction. Clinical manifestations of RP are divided according to location, severity and duration. In the pathological process may involve all types of cartilage and other structures, rich proteoglycans: eyes, internal ear and vessels. So far, a unified approach to the treatment of RP in terms of evidence-based medicine does not exist. Due to the rarity of the disease clinical studies for comparative evaluation of different drugs have been conducted. For relief of attacks polychondritis most commonly used nonsteroidal antiinflammatory drugs (NSAIDs) and glucocorticoid therapy (corticosteroids), but there is no evidence of their impact on the progression of the process and to prevent relapse. <h3>Objectives</h3> to study the efficiency of pulse therapy in patients with RP. <h3>Methods</h3> 4 patients with RP were hospitalized in the clinic of I cardiorheumatological department of Tashkent Medical Academy (TMA). The diagnosis was made on the basis of diagnostic criteria developed by Macadam. All patients underwent clinical, immunological, biochemical studies, chest X-ray, ECG. <h3>Results</h3> Patients were performed following treatment, Prednisolone 30 mg/day per os, NSAIDs and combination pulse therapy course (1st and 3rd - days solumedrol 1.0 g intravenously, the second day solumedrol 1.0 g in combination with cyclophosphamide 800 mg). The therapy was showed improvement of general condition of patients, decreased pain in the cartilage of nose and swelling of ears, back pain, general weakness. Patients were discharged under the supervision of district therapeutist and rheumatologist with recommendations to continue receiving NSAIDs, corticosteroids and program of the pulse therapy for 6 months. <h3>Conclusions</h3> Thus, the use in the treatment of RP pulse therapy had a positive effect on the clinical condition of patients and prevent progression of disease. <h3>Disclosure of Interest</h3> None declared
A 2-Dose Schedule of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Given to Children with Sickle Cell Disease Previously Immunized with 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23): Results of a Phase 3 Study
Authors: Mariane De Montalembert, Miguel R. Abboud, Anne Fiquet, Adlette Inati, Jeffrey D. Lebensburger, Normeen Kaddah, Antonio Piga, Baba Inusa, Qin Jiang, Lisa Pereira, Emilio A. Emini, William C. Gruber, Alejandra Gurtman, Daniel A. Scott
Journal: Blood (2012)
Target Enrichment and High-Throughput Sequencing of 80 Ribosomal Protein Genes to Identify Mutations Associated with Diamond-Blackfan Anaemia.
Authors: Gareth Gerrard, Mikel Valgañón, Hui En Foong, Dalia Kasperaviciute, Michael Müller, Laurence Game, Deena Iskander, Irene Roberts, Letizia Foroni, Josu de la Fuente, Anastasios Karadimitris
Journal: Blood (2012)
AB0724 The Frequency of The Metabolic Syndrome and Comparison of He Risk Factors for Cardiovascular Disease in Psoriasis, PSA and RA Groups: Table 1.
Authors: O. Ozkul, A. Yazici, A. Akturk, D. Karadag, O. Ozdemir, S. Tekeoglu, A. Cefle
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Metabolic syndrome (MetS) increases the risk of developing cardiovascular disease at least two-fold. Various studies have suggested that MetS is associated with a state of chronic, low-grade inflammation (1). <h3>Objectives</h3> Our aim is to show relationships between MetS and chronic low grade inflammatory diseases, to determine frequency of MetS in psoriasis and psoriatic arthritis (PsA) against romatoid arthritis (RA). <h3>Methods</h3> 155 patients were included in this cross-sectional study. Fifty patients were psoriasis, 55 patients were PsA who was diagnosed according to the CASPAR criteria. Fifty patients were seropositive RA who was diagnosed according to the ACR/EULAR 2010 classification criteria. MetS was diagnosed by the 2005 criteria of IDF (2). Cardiovascular risk factors and MetS associated parameters were evaluated. <h3>Results</h3> Patients mean age, age at onset disease and diagnosing age of disease in the RA group were significantly higher compared with the psoriasis and PsA (p=0,002–0,000–0,000; respectively). Duration of psoriasis was 14,7±10,2 years in the PsA group and 12,1±11,7 years in the psoriasis group (p=0,000). Duration of arthritis were significantly longer in the RA group compared with the PsA group (p=0,000). Insulin resistance showed no significant difference between the three groups (%70, %64, %66). Elevated triglyceride levels were higher in the psoriasis and PsA compared with the RA groups (%34, %32,7, %16; respectively; p=0,045). Hypertension ratio was higher in RA than PsA and psoriasis (p=0,011) (Table 1). CRP and HAQ which are parameters for used in the follow up disease activity were higher in the RA group. <h3>Conclusions</h3> In all three groups, the MetS was shown to be higher than the general population. The differences between the groups could not be detected because of the small number of patients, and not equal distribution of population by age and gender. <h3>References</h3> Raychaudhuri S.K, Chatterjee S, Nguyen C, et al. Increased Prevalence of the Metabolic Syndrome in Patients with Psoriatic Arthritis. Metab Syndr and Relat Disord 2010;8(4):331–4. Taylor W, Gladman D, Helliwell P, et al. Classification criteria for Psoriatic Arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54(8):2665–73. <h3>Acknowledgement</h3> None <h3>Disclosure of Interest</h3> None declared
Therapy for Cellulitis
Authors: Juan N. Lessing, Steven McGee
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria
Authors: A. P. Kaplan, A. M. Giménez-Arnau, S. S. Saini
Journal: Allergy (2016)

The monoclonal anti-immunoglobulin E (IgE) antibody, omalizumab, was the first drug approved for use in patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) who remain symptomatic despite H1-antihistamine treatment. Omalizumab binds to free IgE, which lowers free IgE levels and causes FcεRI receptors on basophils and mast cells to be downregulated. It has been shown to improve symptoms of CIU/CSU, but its mechanism of action is not currently understood. Potential mechanisms in CIU/CSU include reducing mast cell releasability, reversing basopenia and improving basophil IgE receptor function, reducing activity of IgG autoantibodies against FcεRI and IgE, reducing activity of IgE autoantibodies against an antigen or autoantigen that has yet to be definitively identified, reducing the activity of intrinsically 'abnormal' IgE, and decreasing in vitro coagulation abnormalities associated with disease activity. However, none of these theories alone or in combination fully account for the pattern of symptom improvement seen with omalizumab therapy, and therefore, no one mechanism is likely to be the definitive mechanism of action. Additional research is needed to further clarify the involvement of omalizumab in relieving symptoms associated with the complex, multifactorial pathogenesis of CIU/CSU.
A Novel Inherited Single-Nucleotide Mutation in 5′-UTR in the Transcription Factor RUNX1 in Familial Platelet Disorder with Propensity To Develop Myeloid Malignancies.
Authors: Keita Kirito, Toru Mitsumori, Takahiro Nagashima, Masae Kunitama, Kei Nakajima, Kozue Yoshida, Yongzhen Hu, Mitsuhiro Yanagai, Norio Komatsu
Journal: Blood (2006)
Peripheral Blood Progenitor Cell Collection in Low-Weight Infants (36 patients; 69 Large Volume Leukapheresis Procedures)
Authors: Sergio Pereira Chacim, Susana Roncon, Isabel Barbosa, Bernardo Bollen Pinto, Alcina Avila, Sara Ferreira, Helena Leal, Sergio Machado, Alzira Carvalhais
Journal: Blood (2008)
Decreased Platelet Thrombus Size, Due to a Heightened Proteolysis of VWF By ADAMTS13, Is Quickly Restored after Valve Replacement in Aortic Stenosis Patients
Authors: Hideo Yagi, Masaki Hayakawa, Naoko Yamaguchi, Keigo Yamashita, Shigeki Taniguchi, Masanori Matsumoto, Kazuo Tsubaki, Yoshihiro Fujimura
Journal: Blood (2014)
Skin Immune Stimulation By Infections and Drug Toxicities during Induction and/or Consolidations Increases Incidence of Skin Acute Graft Versus Host Disease in Acute Myeloid Leukemia: A Study on Behalf of SFGM-TC and ALFA
Authors: Lining Wang, Emmanuel Raffoux, Xavier Thomas, Ibrahim Yakoub-Agha, Jean Henri Bouhris, Stephane de Botton, Mauricette Michallet, Stephanie Nguyen quoc, Sylvain P Chantepie, Eric Deconinck, Denis Caillot, Pascal Turlure, Stephane Vigouroux, Arnaud Pigneux, Anne Huynh, Jean Valère Malfuson, Michael Loschi, Gerard Socie, Herve Dombret, Regis Peffault de la Tour, Thomas Cluzeau
Journal: Blood (2015)
The Treatment Cost To Achieve a Complete Cytogenetic Response in Imatinib Resistant Chronic Phase (CP) Chronic Myelogenous Leukemia (CML) Patients: Nilotinib vs. Dasatinib.
Authors: Fabio D. Mataveli, Weiwei Feng, Alessandra Calabró, Wellington Mendes, Vania Hungria
Journal: Blood (2007)
Sustained Long Term Engraftment and Transgene Expression of Peripheral Blood CD34+ Cells Transduced with Advanced Lentiviral Vectors in the Preence of ABC Inhibitors.
Authors: Wanda Piacibello, Melania Tesio, Loretta Gammaitoni, Monica Gunetti, Ymera Pignochino, Massimo Aglietta
Journal: Blood (2004)
Maitake Mushroom Extract in Myelodysplastic Syndrome (MDS): A Phase II Study
Authors: Kathleen M. Wesa, Virginia M. Klimek, Susanna Cunningham-Rundles, Allison Hirsch, Emily K. Dolezal, Gria N Jacobs, Marci I Coleton, Stephen D. Nimer, Barrie R. Cassileth
Journal: Blood (2011)
Severe Post Thrombotic Syndrome Is Associated to Lower Echogenicity of the Residual Venous Thrombosis
Authors: Bruna M Mazetto, Fernanda Loureiro de Andrade Orsi, Sandra A.F Silveira, Mariane Cristina Flores-Nascimento, Luis Fernando Bittar, Isadora Custódio, Joyce M Annichino-Bizzacchi
Journal: Blood (2014)
Graft-Versus-Leukemia (GVL) Effect After Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) as Treatment for Acute Myeloid Leukemia (AML): a Survey From the Acute Leukemia Working Party of the EBMT.
Authors: Frederic Baron, Myriam Labopin, Mohamad Mohty, Nadezda Basara, Dietger Niederwieser, Noel-Jean Milpied, J. J. Cornelissen, Claes Malm, Henrik Sengeloev, Didier Blaise, Jeroen JWM Janssen, Eefke Petersen, Gerard Socie, Vanderson Rocha
Journal: Blood (2009)
CCL-2 Is a KIT D816V-Dependent Modulator of Bone Marrow Remodeling and Microenvironmental Alterations in Systemic Mastocytosis
Authors: Georg Greiner, Nadine Witzeneder, Klaus Schmetterer, Theresia Popow-Kraupp, Wolfgang R Sperr, Peter Valent, Matthias Mayerhofer, Gregor Hoermann
Journal: Blood (2015)
OP0188 The Dose of Glucocorticoids Taken at One Year, but Not The Initial Dose Prescribed, Is An Independent Predictor of Damage Accrual in Lupus Nephritis
Authors: A. El Mourad, S. Nieuwland-Husson, G. Depresseux, F.A. Houssiau
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Several studies have demonstrated the pivotal role of glucocorticoids (GC) in damage accrual in lupus patients but very few studies were selectively performed in the subgroup of patients suffering from lupus nephritis (LN). <h3>Objectives</h3> To define the predictors of damage accrual in a LN population. <h3>Methods</h3> We reviewed the files of the 146 patients with biopsy-proven LN included in the Louvain Lupus Nephritis Cohort. The following data were retrieved: demographics, renal pathology, standard renal parameters at baseline and last followup, treatment, renal relapses and SLICC/ACR-DI over time. <h3>Results</h3> After a mean followup period of 124 months, 76/146 patients (52%) had some damage, <i>i. e.</i> a SLICC/ACR-DI ≠ 0. The renal, musculoskeletal, cardiovascular and ocular items were the most represented. By univariate analyses, patients with a SLICC/ACR-DI ≠ 0 were older, had a longer followup, took more GC at one year [methylprednisolone (MP): 8.8 mg/d <i>vs</i> 5.7], had suffered from more renal relapses and had develop more renal impairment, including end-stage renal disease. Similar data were obtained if a different SLICC/ACR-DI cutoff value was used (&gt;1 <i>vs</i> ≤1). In a multivariate analysis, using the logistic likelihood ratio test, only 3 variables independently predicted damage, namely the length of followup, the presence of renal relapses and the MP daily dose taken at one year. By contrast, gender, ethnicity, age of onset, standard renal parameters, renal pathology, starting oral MP daily dose, use of IV MP or IV CY did not predict damage. Time to first SLICC/ACR-DI point was statistically shorter, by Kaplan-Meier survival curves, in patients taking ≥4 mg/d of MP after one year of treatment compared to &lt;4 mg/d. Again the initial dose of MP was not influential. Every additional mg/d of MP taken at one year increased the risk of having a SLICC/ACR-DI ≠ 0 by 26% (HR: 1.26; CI: 1.02–1.55). <h3>Conclusions</h3> We confirm that more than half of LN patients develop damage over time according to the SLICC/ACR-DI. Interestingly, the dose of GC taken at one year (and not the initial dose prescribed) is an independent predictor of damage accrual. <h3>Disclosure of Interest</h3> None declared